GlassScriptPhysician profile
Shilpa J Mehta
NPI 1548422991
$7,973.15
in general payments reported to CMS, 2019-2025
48 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $670 · 2021: $1,817 · 2022: $1,661 · 2023: $942 · 2024: $624 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $978.15 | 2019-2024 | Mounjaro, Trulicity, Lyumjev |
| Novo Nordisk INC | $849.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.95 | 2019-2025 | Jardiance |
| Mannkind Corporation | $508.27 | 2020-2025 | Afrezza |
| Insulet Corporation | $456.24 | 2021-2025 | Omnipod, Omnipod |
| Abbvie INC. | $407.90 | 2021-2025 | |
| Corcept Therapeutics | $405.09 | 2020-2025 | Korlym |
| Amgen INC. | $395.29 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $355.44 | 2021-2025 | |
| Abbott Laboratories | $337.41 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $320.37 | 2019-2025 | |
| Dexcom, INC. | $304.25 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $229.91 | 2019-2025 | Airsupra |
| Xeris Pharmaceuticals, INC. | $200.11 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Zealand Pharma US, INC. | $181.17 | 2020-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Antares Pharma, INC. | $110.37 | 2020-2022 | |
| Amarin Pharma, INC. | $79.18 | 2020-2022 | |
| Cequr Corporation | $77.53 | 2022-2023 | Cequr Simplicity |
| Pfizer INC. | $76.18 | 2020-2025 | |
| Madrigal Pharmaceuticals | $75.48 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $75.25 | 2025 | |
| Embecta Corp. | $72.16 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Medtronic Minimed, INC. | $61.25 | 2020 | |
| Alexion Pharmaceuticals, INC. | $58.05 | 2021-2024 | Strensiq |
| Astellas Pharma US INC | $56.14 | 2024-2025 | Veozah |
| Tandem Diabetes Care, INC. | $46.08 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Valeritas, INC. | $42.96 | 2019 | |
| Opko Pharmaceuticals, LLC | $41.22 | 2023-2024 | Rayaldee |
| Dutch Ophthalmic, USA | $38.40 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $31.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.23 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $30.03 | 2021-2024 | Contrave |
| Ibsa Pharma INC. | $29.71 | 2022-2023 | Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $29.17 | 2025 | Yorvipath |
| Tolmar, INC. | $26.54 | 2023 | |
| Medtronic, INC. | $25.28 | 2023 | Minimed 780g |
| Halozyme INC | $22.22 | 2023 | |
| Allergan, INC. | $21.36 | 2020 | |
| Radius Health, INC. | $21.29 | 2025 | Tymlos |
| Acerus Pharmaceuticals Corporation | $21.01 | 2020 | |
| Mallinckrodt Hospital Products INC. | $19.27 | 2025 | Acthar |
| Agile Therapeutics, INC. | $19.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.78 | 2019 | |
| Alvogen INC | $17.15 | 2022 | |
| Depuy Synthes Sales INC. | $15.71 | 2019 | |
| Horizon Therapeutics Plc | $13.66 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.